New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
17:46 EDTMNKMallinckrodt announces settlement of Ofirmev injection patent litigation
Mallinckrodt announced that its subsidiary, Cadence Pharmaceuticals, has entered into settlement and license agreements with Fresenius Kabi USA resolving pending patent litigation involving Ofirmev injection. The companies are not disclosing specific terms of the settlement and license agreements, except that Cadence has granted Fresenius Kabi a non-exclusive right to market an intravenous acetaminophen product in the U.S. under Fresenius Kabiís NDA on December 6, 2020, or earlier under certain circumstances. Mallinckrodtís subsidiary Cadence has two patents covering Ofirmev listed in the Orange Book, the last of which will expire on June 6, 2021. Cadence had filed suit against Fresenius Kabi in January 2013.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
11:25 EDTMNKMallinckrodt management to meet with Jefferies
Meetings to be held in Boston/New York on April 21-22 hosted by Jefferies.
07:41 EDTMNKEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 13, 2015
17:32 EDTMNKMallinckrodt says Questcor to pay $38M in proposed settlement
Subscribe for More Information
April 8, 2015
08:56 EDTMNKPerrigo's ANDA for equivalent of Mallinckrodt's Exalgo approved by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use